{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:40:36Z","timestamp":1785249636738,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020209","name":"Shaanxi Provincial Health Commission","doi-asserted-by":"publisher","award":["2021D003"],"award-info":[{"award-number":["2021D003"]}],"id":[{"id":"10.13039\/501100020209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016112","name":"Xi'an Science and Technology Association","doi-asserted-by":"publisher","award":["095920211312"],"award-info":[{"award-number":["095920211312"]}],"id":[{"id":"10.13039\/501100016112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ajp.2023.103699","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T21:58:38Z","timestamp":1689199118000},"page":"103699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A 5-year retrospective study of amisulpride steady-state plasma concentration in patients with schizophrenia in real-life settings based on therapeutic drug monitoring data"],"prefix":"10.1016","volume":"87","author":[{"given":"Jing","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajp.2023.103699_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007691-200404000-00010","article-title":"Therapeutic drug monitoring of psychotropic drugs. TDM \u201cnouveau\u201d","volume":"26","author":"Bengtsson","year":"2004","journal-title":"Ther. Drug. Monit."},{"issue":"3","key":"10.1016\/j.ajp.2023.103699_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.euroneuro.2003.09.001","article-title":"Plasma amisulpride levels in schizophrenia or schizoaffective disorder","volume":"14","author":"Bergemann","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.ajp.2023.103699_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hup.2256","article-title":"Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010","volume":"27","author":"Bowskill","year":"2012","journal-title":"Hum. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.ajp.2023.103699_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.12740\/PP\/OnlineFirst\/109129","article-title":"Amisulpride-is it as all other medicines or is it different? An update","volume":"54","author":"Hadry","year":"2020","journal-title":"Psychiatr. Pol."},{"issue":"2","key":"10.1016\/j.ajp.2023.103699_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration\u2013effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges","volume":"41","author":"Hiemke","year":"2019","journal-title":"Ther. Drug. Monit."},{"issue":"1\u201302","key":"10.1016\/j.ajp.2023.103699_bib6","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2023.103699_bib7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/FTD.0000000000000585","article-title":"A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting","volume":"41","author":"Jonsson","year":"2019","journal-title":"Ther. Drug. Monit."},{"issue":"6","key":"10.1016\/j.ajp.2023.103699_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2045125311426896","article-title":"Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study","volume":"1","author":"Kotan","year":"2011","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.ajp.2023.103699_bib9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3111\/13696998.2013.816310","article-title":"Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commerciallyinsured patients with schizophrenia","volume":"16","author":"Lang","year":"2013","journal-title":"J. Med. Econ."},{"issue":"4","key":"10.1016\/j.ajp.2023.103699_bib10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bcp.14246","article-title":"A systematic review and combined meta\u2010analysis of concentration of oral amisulpride","volume":"86","author":"Li","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2023.103699_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hup.574","article-title":"Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study","volume":"19","author":"Linden","year":"2004","journal-title":"Hum. Psychopharmacol."},{"issue":"05","key":"10.1016\/j.ajp.2023.103699_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2008-1076727","article-title":"Striatal D2\/D3 receptor occupancy, clinical response and side effects with amisulpride: an Iodine-123-Iodobenzamide SPET Study","volume":"41","author":"Meisenzahl","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2023.103699_bib13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/0269881108089806","article-title":"Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder","volume":"23","author":"Muller","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2023.103699_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2006-931540","article-title":"Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study","volume":"39","author":"M\u00fcller","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.ajp.2023.103699_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jpsychires.2005.10.003","article-title":"Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia","volume":"41","author":"M\u00fcller","year":"2007","journal-title":"J. Psychiatr. Res"},{"issue":"6","key":"10.1016\/j.ajp.2023.103699_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/YIC.0000000000000420","article-title":"Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data","volume":"37","author":"Qu","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.ajp.2023.103699_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","article-title":"Amisulpride-dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring","volume":"120","author":"Sparshatt","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"issue":"49","key":"10.1016\/j.ajp.2023.103699_bib18","article-title":"Study on the relationship among dose, concentration and clinical response in Chinese schizophrenic patients treated with Amisulpride","volume":"62","author":"Sun","year":"2021","journal-title":"Asian J. Psychiatr."},{"issue":"4","key":"10.1016\/j.ajp.2023.103699_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1461145704004353","article-title":"High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia","volume":"7","author":"Vernaleken","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.ajp.2023.103699_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bmc.3928","article-title":"Development of a UPLC-MS\/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients","volume":"31","author":"Wang","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ajp.2023.103699_bib21","doi-asserted-by":"crossref","first-page":"7901670","DOI":"10.1155\/2017\/7901670","article-title":"Effect of peony-glycyrrhiza decoction on amisulpride-induced hyperprolactinemia in women with schizophrenia: a preliminary study","volume":"2017","author":"Yang","year":"2017","journal-title":"Evid. Based Complement Altern. Med."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201823002551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201823002551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:48:49Z","timestamp":1761756529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201823002551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":21,"alternative-id":["S1876201823002551"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2023.103699","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 5-year retrospective study of amisulpride steady-state plasma concentration in patients with schizophrenia in real-life settings based on therapeutic drug monitoring data","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2023.103699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103699"}}